Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

BACKGROUND: The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), disease progression and magnetic resonance imaging (MRI) activity, with a favorabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Aaron E, O’Connor, Paul, Wolinsky, Jerry S, Confavreux, Christian, Kappos, Ludwig, Olsson, Tomas P, Truffinet, Philippe, Wang, Lin, D’Castro, Laura, Comi, Giancarlo, Freedman, Mark S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2012
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573676/
https://www.ncbi.nlm.nih.gov/pubmed/22723573
http://dx.doi.org/10.1177/1352458512450354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573676/
https://www.ncbi.nlm.nih.gov/pubmed/22723573
http://dx.doi.org/10.1177/1352458512450354

Ejemplares similares